[go: up one dir, main page]

SK3442001A3 - Dry powder active agent pulmonary delivery - Google Patents

Dry powder active agent pulmonary delivery Download PDF

Info

Publication number
SK3442001A3
SK3442001A3 SK344-2001A SK3442001A SK3442001A3 SK 3442001 A3 SK3442001 A3 SK 3442001A3 SK 3442001 A SK3442001 A SK 3442001A SK 3442001 A3 SK3442001 A3 SK 3442001A3
Authority
SK
Slovakia
Prior art keywords
particles
powder
hygroscopic
active ingredient
hygroscopic growth
Prior art date
Application number
SK344-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Andrew Clark
Mei-Chang Kuo
Cecily Lalor
Barry John Aldous
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of SK3442001A3 publication Critical patent/SK3442001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
SK344-2001A 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery SK3442001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14
PCT/US1999/021109 WO2000015262A1 (fr) 1998-09-14 1999-09-13 Administration par voie pulmonaire d'un agent actif sous forme de poudre seche

Publications (1)

Publication Number Publication Date
SK3442001A3 true SK3442001A3 (en) 2001-11-06

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
SK344-2001A SK3442001A3 (en) 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery

Country Status (44)

Country Link
EP (1) EP1117442A1 (fr)
JP (1) JP2002524535A (fr)
KR (1) KR20010075063A (fr)
CN (1) CN1317977A (fr)
AP (1) AP1374A (fr)
AR (1) AR022090A1 (fr)
AU (1) AU753014B2 (fr)
BG (1) BG105430A (fr)
BR (1) BR9913722A (fr)
CA (1) CA2343920A1 (fr)
CO (1) CO5130023A1 (fr)
CZ (1) CZ2001829A3 (fr)
DZ (1) DZ2892A1 (fr)
EA (1) EA003476B1 (fr)
EE (1) EE200100151A (fr)
GE (1) GEP20043257B (fr)
GT (1) GT199900156A (fr)
HK (1) HK1042231A1 (fr)
HN (1) HN1999000159A (fr)
HR (1) HRP20010189A2 (fr)
HU (1) HUP0103837A3 (fr)
ID (1) ID28845A (fr)
IL (2) IL141562A0 (fr)
IS (1) IS5878A (fr)
LT (1) LT4897B (fr)
LV (1) LV12658B (fr)
MA (1) MA25590A1 (fr)
MY (1) MY129282A (fr)
NO (1) NO20011251L (fr)
NZ (1) NZ510168A (fr)
OA (1) OA11781A (fr)
PA (1) PA8481901A1 (fr)
PE (1) PE20001061A1 (fr)
PL (1) PL195574B1 (fr)
SA (1) SA99200718B1 (fr)
SK (1) SK3442001A3 (fr)
TN (1) TNSN99173A1 (fr)
TR (1) TR200101182T2 (fr)
TW (1) TWI226248B (fr)
UA (1) UA76085C2 (fr)
UY (1) UY25711A1 (fr)
WO (1) WO2000015262A1 (fr)
YU (1) YU24201A (fr)
ZA (1) ZA200101995B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
JP4874483B2 (ja) 1999-06-09 2012-02-15 ロバート イー． シーバース 超臨界流体補助ネブライゼーション及びバブル乾燥
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
CA2446904A1 (fr) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
EG24184A (en) 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
CA2465675C (fr) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Compositions particulaires ameliorees destinees a etre administrees par voie pulmonaire
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
UA83341C2 (uk) 2002-02-25 2008-07-10 Дифьюжен Фармасьютикалз Ллк Біополярні солі транс-каротиноїдів та їх використання
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
CA2511385A1 (fr) * 2002-12-19 2004-07-22 Pharmacia Corporation Intermediaire pour formulation a caractere non-hygroscopique acceptable comprenant un bouchon hydroscopique
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2909080T3 (es) 2004-04-23 2022-05-05 Cydex Pharmaceuticals Inc Formulación de DPI que contiene sulfoalquil éter ciclodextrina
US8030350B2 (en) 2005-02-24 2011-10-04 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
BRPI0608844A2 (pt) * 2005-03-09 2010-02-02 Ono Pharmaceutical Co partìcula e preparação que contém a partìcula
ES2526903T3 (es) 2005-10-26 2015-01-16 Cydex Pharmaceuticals, Inc. Composiciones de sulfoalquiléter ciclodextrina y métodos de preparación de las mismas
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20080035143A1 (en) * 2006-08-14 2008-02-14 Sievers Robert E Human-powered dry powder inhaler and dry powder inhaler compositions
KR20090081407A (ko) * 2006-10-25 2009-07-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 고결 방지 과립상 제제
EP1925295A1 (fr) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Formule de poudre stable contenant un nouveau anticholinergique
MX2009010988A (es) 2007-04-13 2010-03-15 Diffusion Pharmaceuticals Llc Uso de trans-carotenoides bipolares como un tratamiento previo y en el tratamiento de una enfermedad vascular periferica.
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
MX2010004803A (es) 2007-10-31 2010-09-09 Diffusion Pharmaceuticals Llc Una nueva clase de composiciones terapeuticas que mejoran la difusion de moleculas pequeñas.
US9610343B2 (en) * 2009-05-20 2017-04-04 Aeras Global Tb Vaccine Foundation Stable, spray dryed, immunogenic, viral compositions
EP2445339B1 (fr) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Composé améliorant la diffusion et son utilisation avec un thrombolytique
ES2654945T3 (es) 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Formulaciones orales de carotenoides trans bipolares
US9682096B2 (en) 2012-05-02 2017-06-20 Janssen R & D Ireland Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections
WO2014074797A1 (fr) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Poudres pulmonaires de densité ultra basse
WO2015042352A1 (fr) * 2013-09-20 2015-03-26 Virginia Commonwealth University Administration de particules à l'aide d'excipients hygroscopiques
CA2965759C (fr) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Polypeptides en poudre presentant moins d'impuretes de disulfide comprenant des materiaux cationiques divalents
WO2017165667A1 (fr) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Utilisation de caroténoïdes trans bipolaires avec une chimiothérapie et une radiothérapie en vue du traitement d'un cancer
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
ATE222754T1 (de) * 1992-06-12 2002-09-15 Teijin Ltd Ultrafeines pulver zur inhalation und dessen herstellung
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998031346A1 (fr) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
UA76085C2 (en) 2006-07-17
IS5878A (is) 2001-03-05
CN1317977A (zh) 2001-10-17
IL141562A0 (en) 2002-03-10
HUP0103837A3 (en) 2002-11-28
CZ2001829A3 (cs) 2001-09-12
KR20010075063A (ko) 2001-08-09
TWI226248B (en) 2005-01-11
PL346768A1 (en) 2002-02-25
EP1117442A1 (fr) 2001-07-25
ZA200101995B (en) 2002-03-11
HUP0103837A2 (hu) 2002-05-29
BG105430A (en) 2001-12-29
AP2001002093A0 (en) 2001-03-31
TR200101182T2 (tr) 2001-09-21
CO5130023A1 (es) 2002-02-27
MY129282A (en) 2007-03-30
GT199900156A (es) 2001-03-07
WO2000015262A1 (fr) 2000-03-23
HRP20010189A2 (en) 2005-04-30
PE20001061A1 (es) 2000-10-08
IL141562A (en) 2007-07-24
TNSN99173A1 (fr) 2005-11-10
LV12658A (lv) 2001-05-20
SA99200718B1 (ar) 2006-11-04
AR022090A1 (es) 2002-09-04
CA2343920A1 (fr) 2000-03-23
BR9913722A (pt) 2001-05-29
LT2001021A (en) 2001-11-26
PA8481901A1 (es) 2002-04-25
UY25711A1 (es) 1999-11-17
AP1374A (en) 2005-02-28
LT4897B (lt) 2002-02-25
EA003476B1 (ru) 2003-06-26
ID28845A (id) 2001-07-05
LV12658B (lv) 2001-09-20
NO20011251L (no) 2001-04-17
HK1042231A1 (zh) 2002-08-09
JP2002524535A (ja) 2002-08-06
AU753014B2 (en) 2002-10-03
EE200100151A (et) 2002-06-17
MA25590A1 (fr) 2002-12-31
GEP20043257B (en) 2004-06-25
OA11781A (en) 2005-07-26
DZ2892A1 (fr) 2003-12-15
AU6039799A (en) 2000-04-03
EA200100300A1 (ru) 2001-10-22
NO20011251D0 (no) 2001-03-13
PL195574B1 (pl) 2007-10-31
YU24201A (sh) 2003-08-29
HN1999000159A (es) 1999-11-11
NZ510168A (en) 2003-09-26

Similar Documents

Publication Publication Date Title
SK3442001A3 (en) Dry powder active agent pulmonary delivery
JP4859320B2 (ja) 改良された分散性を有する乾燥粉末組成物
KR100620338B1 (ko) 에어로졸형 활성 제제 전달 방법
US6582728B1 (en) Spray drying of macromolecules to produce inhaleable dry powders
JP2003513031A5 (fr)
JP2009136688A (ja) 流動抵抗調節されたエアロゾル化活性薬剤送達
PL179443B1 (pl) Kompozycja insuliny, sposób wytwarzania kompozycji insuliny i sposób wytwarzania dawki insuliny w postaci aerozolu PL PL PL PL
SK7772001A3 (en) Particles of amino acid, process for their preparation, powder containing same, process for the preparation of such powder, an inhalator containing such powder, and their use
SI9720031A (sl) Zmesi dispergiranih makromolekul in metode njihove priprave in uporabe
MXPA01002649A (en) Dry powder active agent pulmonary delivery
Batycky et al. The development of large porous particles for inhalation drug delivery
HK1092687B (en) Dry powder compositions having improved dispersivity
AU2369599A (en) Pulmonary delivery of aerosolized medicaments